Abstract | AIM: METHODS: RESULTS: At study end, the group randomized to the simvastatin/ rosiglitazone combination had a greater reduction in hs-CRP of 1.33 mg/dl, (p = 0.029) and showed a trend for a greater reduction in urinary isoprostane (-39%), (p = 0.056) compared to simvastatin/placebo group. Changes in MDA levels did not differed between groups (p = 0.81). 24-h systolic blood pressure (SBP) also showed a 4.5 mmHg reduction at 6 months (p = 0.06). Adiponectin levels increased by 3.91 µg/ml in the combination group over placebo, (p = 0.03) and blood glucose decreased in combination group vs. placebo. CONCLUSION:
|
Authors | I Lazich, P Sarafidis, E de Guzman, A Patel, R Oliva, G Bakris |
Journal | Diabetes, obesity & metabolism
(Diabetes Obes Metab)
Vol. 14
Issue 2
Pg. 181-6
(Feb 2012)
ISSN: 1463-1326 [Electronic] England |
PMID | 21955403
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © 2011 Blackwell Publishing Ltd. |
Chemical References |
- Adiponectin
- Blood Glucose
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Hypolipidemic Agents
- Isoprostanes
- Lipids
- Thiazolidinediones
- Rosiglitazone
- Malondialdehyde
- C-Reactive Protein
- Simvastatin
|
Topics |
- Adiponectin
(blood)
- Adult
- Aged
- Blood Glucose
(drug effects)
- Blood Pressure
(drug effects)
- Blood Pressure Monitoring, Ambulatory
- C-Reactive Protein
(drug effects)
- Coronary Artery Disease
(physiopathology, prevention & control)
- Double-Blind Method
- Drug Therapy, Combination
- Female
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
(therapeutic use)
- Hypolipidemic Agents
(therapeutic use)
- Inflammation
(blood, drug therapy)
- Isoprostanes
(urine)
- Lipids
(blood)
- Male
- Malondialdehyde
(blood)
- Metabolic Syndrome
(drug therapy, physiopathology)
- Middle Aged
- Oxidative Stress
(drug effects)
- Rosiglitazone
- Simvastatin
(therapeutic use)
- Thiazolidinediones
(therapeutic use)
|